Cell-specific expression of the analgesic-antitumor peptide coding sequence under the control of the human α-fetoprotein gene promoter and enhancer

Jin,Sisi; Lin,Xianfan; Guan,Huaqin; Wu,Jinming

doi:10.3892/etm.2015.2166

Cell-specific expression of the analgesic-antitumor peptide coding sequence under the control of the human α-fetoprotein gene promoter and enhancer

Authors:
- Sisi Jin
- Xianfan Lin
- Huaqin Guan
- Jinming Wu
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang 325000, P.R. China
Published online on: January 2, 2015 https://doi.org/10.3892/etm.2015.2166
Pages: 863-867

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to construct a gene‑modified hepatocellular carcinoma (HCC)‑specific analgesic‑antitumor peptide (AGAP) expression vector regulated by the α‑fetoprotein (AFP) promoter and enhancer, in order to evaluate its effect. The AFP promoter is generally used in HCC‑specific gene therapy strategies. However, this approach is limited by the weak activity of the AFP promoter. Linking the AFP enhancer and promoter has been shown to generate a stronger and more HCC‑selective promoter. The AGAP DNA fragment was amplified from the total RNA of the Chinese scorpion, Buthus martensii Karsch. The fragment was subsequently cloned into the pAFP plasmid with the minimal essential DNA fragment, which included the AFP gene promoter and enhancer, to construct the recombinant plasmid, pAFP‑AGAP. The plasmid was transfected into HepG2 cells and the mRNA expression levels of AGAP were detected by reverse transcription polymerase chain reaction (RT‑PCR). In addition, Cell Counting Kit 8 (CCK‑8) was used to analyze the cytotoxicity of plasmid transfection. The length, position and orientation of the inserted AGAP gene were all confirmed to be correct; thus, the recombinant vector was successfully constructed. Using RT‑PCR and CCK‑8 analysis, the mRNA expression levels of AGAP and the cytotoxicity in AFP‑producing human HCC cells were determined. The AFP promoter and enhancer were found to specifically accelerate the expression of the target genes within the cells that were positive for AFP. Therefore, the method used in the present study was demonstrated to be a novel integration of traditional Chinese medicine with western medicine.

View Figures

View References

1	Farmer DG and Busuttil RW: The role of multimodal therapy in the treatment of hepatocellular carcinoma. Cancer. 73:2669–2670. 1994. View Article : Google Scholar : PubMed/NCBI
2	Levin B and Amos C: Therapy of unresectable hepatocellular carcinoma. N Engl J Med. 332:1294–1296. 1995. View Article : Google Scholar : PubMed/NCBI
3	Villanueva A and Llovet JM: Targeted therapies for hepatocellular carcinoma. Gastroenterology. 140:1410–1426. 2011. View Article : Google Scholar : PubMed/NCBI
4	Gutierrez AA, Lemoine NR and Sikora K: Gene therapy for cancer. Lancet. 339:715–721. 1992. View Article : Google Scholar : PubMed/NCBI
5	Liu YF, Hu J, Zhang JH, Wang SL and Wu CF: Isolation purification, and N-terminal partial sequence of an antitumoral peptide from the venom of the Chinese scorpion Buthus martensii Karsch. Prep Biochem Biotechnol. 32:317–327. 2002. View Article : Google Scholar : PubMed/NCBI
6	Abelev GI: Alpha-fetoprotein in ontogenesis and its association with malignant. Adv Cancer Res. 14:295–358. 1971. View Article : Google Scholar
7	Kang JH, Toita R and Murata M: Liver cell-targeted delivery of therapeutic molecules. Crit Rev Biotechnol. Jul 15–2014.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
8	Li W, Li DM, Chen K, et al: Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the α-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study. BMC Cancer. 12:5472012. View Article : Google Scholar
9	Moolten FL: Drug sensitivity (‘suicide’) genes for selective cancer chemotherapy. Cancer Gene Ther. 1:279–287. 1994.PubMed/NCBI
10	Hu Y, Shen Y, Ji B, et al: Liver-specific gene therapy of hepatocellular carcinoma by targeting human telomerase reverse transcriptase with pegylated immuno-lipopolyplexes. Eur J Pharm Biopharm. 78:320–325. 2011. View Article : Google Scholar : PubMed/NCBI
11	Gaun M, Rodriguez-Madoz JR, Alzuguren P, et al: Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector. Cancer Res. 66:1620–1629. 2006. View Article : Google Scholar
12	Tan YH and Guo JS: Research advances in chemical component and analgesic effect of Buthus martensii Karsch. Hunan Zhong Yi Yao Daobao. 7:210–212. 2001.
13	Zhou XH, Yang D, Zhang JH, Liu CM and Lei KJ: Purification and N-terminal partial sequence of anti-epilepsy peptide from venom of the scorpion Buthus martensii Karsch. Biochem J. 257:509–517. 1989.PubMed/NCBI
14	Gu Y, Liu SL, Ju WZ, Li CY and Cao P: Analgesic-antitumor peptide induces apoptosis and inhibits the proliferation of SW480 human colon cancer cells. Oncol Lett. 5:483–488. 2013.PubMed/NCBI
15	Mao Q, Ruan J, Cai X, et al: Antinociceptive effects of analgesic-antitumor peptide (AGAP), a neurotoxin from the scorpion Buthus martensii Karsch, on formalin-induced inflammatory pain through a mitogen-activated protein kinases-dependent mechanism in mice. PLoS One. 8:e782392013. View Article : Google Scholar : PubMed/NCBI
16	Tilghman SM: The structure and regulation of the alpha-fetoprotein and albumin genes. Oxf Surv Eukaryot Genes. 2:160–206. 1985.PubMed/NCBI
17	Selten GC, Princen HM, Selten-Versteegen AM, Mol-Backx GP and Yap SH: Sequence content of alpha-fetoprotein, albumin and fibrinogen polypeptide mRNAs in different organs, developing tissues and in liver during carcinogenesis in rats. Biochim Biophys Acta. 699:131–137. 1982. View Article : Google Scholar : PubMed/NCBI
18	Marrero JA, Su GL, Wei W, et al: Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 37:1114–1121. 2003. View Article : Google Scholar : PubMed/NCBI
19	Wu L, Matherly J, Smallwood A, Adams JY, Billick E, Belldegrun A and Carey M: Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther. 8:1416–1426. 2001. View Article : Google Scholar : PubMed/NCBI
20	Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WG Jr and Fine HA: Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med. 3:1145–1149. 1997. View Article : Google Scholar : PubMed/NCBI
21	Huang TG, Savontaus MJ, Shinozaki K, Sauter BV and Woo SL: Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther. 10:1241–1247. 2003. View Article : Google Scholar : PubMed/NCBI